3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Surgical Wound Infection
4
Neoplasms
4
Colorectal Neoplasms
3
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sepsis
1
Pancreatic Fistula
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Intestinal Neoplasms
1
Inflammation
1
Infections
1
Hematologic Neoplasms
1
Glioblastoma
1
Fever
1
Febrile Neutropenia
1
Exanthema
1
Emergencies
1
Duodenal Neoplasms
1
Discitis
1
Interventions
Gemcitabine
92
Cisplatin
70
Oxaliplatin
37
Capecitabine
37
durvalumab
29
Fluorouracil
26
pembrolizumab
24
Leucovorin
22
S 1 (combination)
18
Nivolumab
13
Irinotecan
13
Bevacizumab
13
lenvatinib
12
tremelimumab
10
apatinib
8
Trastuzumab
7
Injections
7
Albumin-Bound Paclitaxel
7
130-nm albumin-bound paclitaxel
7
Paclitaxel
6
Immune Checkpoint Inhibitors
6
Docetaxel
6
titanium silicide
5
surufatinib
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Biliary Tract Neoplasms
×
Anti-Bacterial Agents
×
Clear all
NCT03631173
2026-04-28
MINIMUM
Oslo University Hospital
Phase NA
Active not recruiting
201 enrolled